模型与临床试验模拟揭示更高利福平剂量具有更强早期杀菌活性
该研究基于PanACEA HIGHRIF1试验中83例结核患者接受10至40 mg/kg利福平治疗7天的痰液液体培养转阳时间数据,采用半机制时间-事件模型探索暴露-效应关系。利福平暴露是痰菌杀灭速率的显著协变量,暴露越高早期杀菌活性越强;临床试验模拟显示50 mg/kg利福平第7天转阳时间预测中位增加值90%预测区间为7.25–10.3天。
要点
- 利福平暴露与早期杀菌活性间存在显著暴露-效应关系。
- 利福平暴露是痰菌杀灭速率的显著协变量,提高早期杀菌活性。
- 模拟显示50 mg/kg利福平第7天转阳时间中位增加值90%预测区间为7.25–10.3天。
核心结论
- 利福平暴露与早期杀菌活性之间存在显著暴露-效应关系,临床试验模拟显示50 mg/kg利福平具有更强早期杀菌活性。
研究设计与样本
- 基于PanACEA HIGHRIF1试验中83例结核患者的痰液液体培养转阳时间数据,采用半机制时间-事件方法建模。
- 患者接受10 mg/kg利福平(n=8,参照组)或20、25、30、35、40 mg/kg利福平(每组n=15)治疗7天。
主要发现
- 基线培养转阳时间是预测初始细菌载量的显著协变量。
- 利福平暴露是痰菌杀灭速率的显著协变量,导致早期杀菌活性增加。
- 50 mg/kg利福平第7天转阳时间预测中位增加值的90%预测区间为7.25–10.3天。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The currently recommended rifampicin dose (10 mg/kg) for treating tuberculosis is suboptimal. The PanACEA HIGHRIF1 trial evaluated the pharmacokinetics and early bactericidal activity of rifampicin doses of up to 40 mg/kg. Conventional statistical analyses revealed no significant exposure-response relationship. Our objectives were to explore the exposure-response relationship for high-dose rifampicin by using pharmacokinetic-pharmacodynamic modeling and to predict the early bactericidal activity of 50 mg/kg rifampicin. METHODS: Data included time to Mycobacterium tuberculosis positivity of liquid cultures of sputum specimens from 83 patients with tuberculosis who were treated with 10 mg/kg rifampicin (n = 8; reference arm) or 20, 25, 30, 35, or 40 mg/kg rifampicin (n = 15/arm) for 7 days. We used a semimechanistic time-to-event approach to model the time-to-positivity data. Rifampicin exposure and baseline time to culture positivity were explored as covariates. RESULTS: The baseline time to culture positivity was a significant covariate on the predicted initial bacterial load, and rifampicin exposure was a significant covariate on the bacterial kill rate in sputum resulting in increased early bactericidal activity. The 90% prediction interval for the predicted median day 7 increase in time to positivity for 50 mg/kg rifampicin was 7.25-10.3 days. CONCLUSIONS: A significant exposure-response relationship was found between rifampicin exposure and early bactericidal activity. Clinical trial simulations showed greater early bactericidal activity for 50 mg/kg rifampicin. CLINICAL TRIALS REGISTRATION: NCT01392911.
引用
- Svensson RJ, Svensson EM, Aarnoutse RE, et al. Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations. J Infect Dis. 2018. PMID: 29718390. doi:10.1093/infdis/jiy242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。